In 1981, Miller et al. described the association of superior vena caval obstruction with a specific subtype of nonHodgkin's lymphoma, characterised histologically by diffuse large-cell proliferation with sclerosis. Subsequent reports have suggested that this is a discrete clinical and pathological entity (Trump et al., 1982; Yousem et al., 1985; Menestrina et al., 1986; Perron et al., 1986; Scarpa et al., 1987; Jacobson et al., 1988; Lamarre et al., 1989; Todeschini et al., 1990; Al-Sharabati et al., 1991) , although this concept has also been questioned (Lister, 1991) . The disease typically occurs in younger adults and is characterised by the presence of a mediastinal mass. Extranodal sites may be involved, and some series (but not all) have described a propensity for spread to unusual sites such as the kidney (Menestrina et al., 1986; Perron et al., 1986; Todeschini et al., 1990) .
Immunophenotypic and Southern blot analysis have confirmed the tumour to be of B-cell origin (Yousem et al., 1985; Mesentrina et al., 1986; Scarpa et al., 1987 Scarpa et al., , 1991 Lamarre et al., 1989) . In some instances mediastinal large-cell lymphoma with sclerosis (MLCLS) has been found to arise in the thymus (Addis & Isaacson, 1986) , and an origin from native thymic medullary B-lymphocytes has therefore been proposed (Isaacson et al., 1987) . Molecular studies have demonstrated alterations of the c-myc oncogene (Scarpa et al., 1991) .
This retrospective analysis describes the clinical course of 22 consecutive patients identified as having MLCLS over a 14 year period at St Bartholomew's Hospital (SBH).
Patients and methods

Patients
Between March 1978 and January 1992, a total of 399 newly diagnosed patients with high-grade lymphoma (Kiel classification) were referred to the ICRF Department of Medical Oncology. Twenty-one were identified as having the histological features of MLCLS.
Nine patients had originally been classified as having mediastinal high-grade B-cell lymphoma, and a further two patients were identified at histological review for a report about treatment for high-grade lymphoma at SBH. The remainder were identified by reviewing the slides of all patients with lymphoma known to have mediastinal or pulmonary involvement at presentation, referred over a 20 year period.
The clinical characteristics of the group with MLCLS are shown in Table I .
Diagnosis
The diagnosis was based on material obtained at thoractomy (12 patients), lymph node biopsy (seven patients), Tru-cut needle biopsy of a mediastinal mass (two patients) and biopsy of a chest wall mass (one patient). The histology typically showed large pleomorphic blast cells with relatively plentiful cytoplasm which was either weakly eosinophilic or 'water-clear' on haematoxylin and eosin preparations. In Time (years) Figure 1 Duration of remission and survival.
most cases, there was dense sclerosis, which often gave the tumour a packeted appearance; necrosis was also frequently seen. A reactive infiltrate of small T lymphocytes was usually present; in some of the mediastinal biopsies, residual thymic epithelial cells were found on stains for cytokeratins.
Immunophenotyping was performed on paraffin sections alone in six cases and on frozen sections in the remainder. All tumours had a B-cell phenotype (either CD20 or CD22 positive). Only two tumours expressed C3d receptors (CD21) and two tumours were weakly positive for the common acute lymphoblastic leukaemia antigen (CD10). None of the tumours expressed the CD5 antigen. A notable feature was lack of stainable immunoglobulin light or heavy chains in most cases. One patient was originally considered to have Hodgkin's disease and received treatment on that basis. When this was unsuccessful, review of the histology resulted in the diagnosis and subsequent treatment being changed. (Kaplan & Meier, 1973 ).
Treatment
Details of treatment are shown in Table II . The initial treatment reflects the protocols for high-grade lymphoma in use at the time (Whelan et al., 1992; Dhaliwal et al., 1993; Radford et al., 1993) . When this did not result in complete remission being achieved (because of lack of response or an incomplete response), alternative treatment (radiotherapy or chemotherapy) was given in the hope of eventually achieving CR. Thus, in Table II 'initial and subsequent treatment' refers to the treatment or consecutive treatments given in an attempt to achieve the maximum response. The four most recently treated patients have electively received radiotherapy (4,000cGy) to the mediastinum on completion of chemotherapy, following reports in the literature which suggested improved survival with combined modality therapy (Jacobson et al., 1988; Todeschini et al., 1990; Al-Sharabati et al., 1991) .
Results
Response to therapy The response to each phase of treatment and the maximum response achieved are shown in detail in Table II . Complete remission was achieved with the initial chemotherapy in only 4/22 patients, GPR in seven and PPR in four, giving an overall response rate of 15/22 (68%). Seven patients showed no evidence of response, one being moribund on arrival at hospital; despite treatment being commenced, she died within 48 h.
Sixteen of the 17 patients in whom anything less than CR was achieved subsequently received additional, alternative therapy (one chemotherapy, six mediastinal radiotherapy, nine both treatment modalities, Table II ). However, in only two did this result in a further documented radiological response, i.e. GPR becoming CR. In two of the seven patients in whom the initial treatment demonstrably failed, the use of mediastinal radiotherapy or etoposide + high-dose cytosine arabinoside (Whelan et al., 1992) resulted in GPR and PPR being achieved eventually, but in both patients the response was short-lived and both subsequently died. Thus, if maximal rather than initial response is considered, the overall response rate becomes 17/22 (77%) (six CR, six GPR, five PPR). There were no treatment-related deaths.
Duration of remission (Figure 1 ) With a median follow-up of 51 years, 11/22 patients (5/6 CR, 3/6 GPR, 3/5 PPR) remain well without progression between 6 months and 14 years.
Site of recurrence In all patients who developed recurrent disease, the predominant site was again the mediastinum. Survival (Figure 1 ) Twelve of the 22 patients remain alive, one having developed progressive disease despite additional radiotherapy and having subsequently received further, alternative chemotherapy. Ten of the 13 patients presenting with stage II/IIE disease are alive, compared with only two of the nine who had stage IV disease at presentation.
Discussion
These results illustrate the experience of a single centre in the management of a rare subtype of high-grade B-cell lymphoma. The patients were not uniformly treated, reflecting developments in treatment approach. Although the number of patients is small, the results clearly demonstrate that a proportion of patients in whom this diagnosis is made are potentially curable with chemotherapy alone. However, in the majority, complete remission was not achieved with the original treatment; whether it would have been had more intensive initial therapy been used is debatable.
It has been suggested that therapy such as MACOP-B (Klimo & Connors, 1985) improves both remission rate and long-term outcome in patients with this diagnosis (Jacobson et al., 1988; Todeschini et al., 1990; Bertini et al., 1991) ; it has also been reported that radiotherapy, given as consolidation of first remission, is advantageous (Jacobson et al., 1988; Todeschini et al., 1990; Al-Sharabati., 1991) . While the latter contention cannot be proved in this series, half of the patients who remain well without progression did in fact receive radiotherapy at some point (Table II) . In two patients in whom GPR was achieved with the original chemotherapy, radiotherapy did result in a further degree of response, at least by radiological criteria (gallium scans were not performed). On the other hand, in four patients, radiotherapy did not result in any further radiological response.
In patients with lymphoma, it is well established that a residual mediastinal shadow following chemotherapy may not necessarily represent active disease. This observation has most frequently been made in patients with Hodgkin's disease (Jochelson et al., 1985; Chen et al., 1987; Radford et al., 1988) but is also true for patients with high-grade nonHodgkin's lymphoma (Dhaliwal et al., 1993) . In this series, the presence of a residual mediastinal abnormality after treatment certainly did not necessarily imply treatment failure, provided at least a partial (> 50%) response had been achieved. This is in contrast to the situation in patients in whom the initial therapy demonstrably failed, in whom the prognosis was extremely grave. In the latter group, tenuous responses to one or other chemotherapy regimen were sometimes seen, only to be rapidly overtaken by relentless progression of, almost invariably, intrathoracic rather than disseminated disease. The use of myeloablative therapy with autologous bone marrow transplantation might arguably have helped such patients, but on the two occasions in which it was used recurrent lymphoma supervened within months.
Thus, although this is a tumour with a recognisable histological subtype and a typical clinical presentation, the situation for patients with MLCLS overall is no different from that of patients with other types of high-grade B-cell lymphoma. The difference lies in the distribution of disease at presentation, recurrence and progression when, almost invariably, the predominant site remains the mediastinum.
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